Venetoclax Plus Azacitidine

A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Published Results

Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higher-risk myelodysplastic syndrome (MDS)

To date, 12 patients have been enrolled (3 in DL0, 3 in DL1, and 6 in DL2) with a median age of 78 years (range: 67-82). The median bone marrow blasts at enrollment was 9% (range: 6 – 17%) with a median ANC, Hgb, and PLT of 1.15 K/µL, 7.5 mg/dL, and 33 K/µL respectively. When stratified based on cytogenetics, 6 (50%) patients had intermediate risk, 2 (17%) had poor risk, and 4 (33%) had very poor risk cytogenetic alterations. When stratified based on IPSS-R criteria, 2 (16%) had intermediate, 5 (42%) had high, and 5 (42%) had very high risk disease. ASXL1 (50%) and TP53 (42%) mutations were most the common mutations on next generation sequencing. The most frequently observed grade 3-4 adverse events(AE) were cytopenias, occurring in all patients. Four (33%) patients had grade 3-4 cytopenias, either thrombocytopenia or neutropenia, that were attributed to the drug combination, with 3 patients consequently requiring dose reductions. At the time of data cut-off, response was seen in 8 patients with an overall response rate of 75%. The median number of cycles to response was 1 (range: 1-4). One patient achieved a CR. Seven patients achieved a marrow response with 2 having neutrophil recovery and 2 with platelet recovery. Three patients achieved transfusion independence. One patient underwent allogeneic stem cell transplantation after receiving 7 cycles. Four patients had no response with 3 of those having TP53 mutations. With a median follow-up of 13.6 months, the mOS is 8.5 months with a 30-day and 60-day mortality of 8% and 17% respectively. Early mortality was related to infection in 1 patient and disease progression in the other. Conclusions: This phase 1 study in patients with relapsed/refractory HR MDS suggests potential benefit with the addition of Ven to HMA with a 75% overall response and a mOS of 8.5 months. TP53 mutations and complex karyotypes still confer poor prognosis despite the addition of Venetoclax. Overall, this combination was well-tolerated with treatment-related AEs primarily consisting of thrombocytopenia and neutropenia.

2 years agoRead more

Resources

Patient Screener(888) 803-1766

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.